Mason Joe's Album: Wall Photos
Endocannabinoid
System Targeted Therapeutics Market By Roots Analysis
So far, more
than 100 different types of cannabinoids have been identified and there is a
growing body of evidence supporting the benefits of this class of compounds in
offering symptomatic relief for a wide variety of chronic health conditions
London
Roots Analysis has announced the
addition of “Endocannabinoid System Targeted Therapeutics Market,
2020-2030” report to its list of offerings.
Over
time, extensive R&D on the potential health benefits of cannabis, have
enabled medical researchers to identify a number of pharmacologically active
ingredients that offer clinical benefit, minus the addictive properties of the
crude substance. Currently, several stakeholders in the pharmaceutical industry
are actively engaged in the efforts to develop leads based on natural and
synthetic derivatives of cannabinoids.
To order this 250+ page report, which
features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Key Market
Insights
Over 175
drugs targeting the endocannabinoid system are currently under development
Most
cannabinoid-based drug candidates are being developed to target the CB1 and CB2
receptors. Nearly 45% of such drugs are presently being investigated in
clinical trials, while 50% are in the preclinical / discovery phase. Majority of these therapies (60%) are designed for
oral administration.
More than
60 companies claim to develop endocannabinoid system targeted therapeutics
Post
2010, there has been a significant rise in the number of companies working in this
domain; such companies represent 63% of the total number of players. Majority
of the firms engaged in this domain (74%) are based in North America, followed
by those headquartered in Asia-Pacific (16%), Europe (8%) and Latin America
(2%).
Partnership
activity has grown at an annualized rate of 35%, between 2017 and 2019
The
maximum number of partnerships were observed in 2019 within this segment of the
pharmaceutical industry. Majority of these agreements were reported to have
been inked for research purposes (20%). In addition, more than 35 merger /
acquisition deal were signed between 2016 and 2020; service / facility
expansion emerged as the most prominent key value drivers for such agreements.
Close to
600 grants were awarded for supporting research on endocannabinoid system
targeted therapeutics, since 2016
Almost
45% of the total amount awarded in the form of grants, was under the R01 (in
support of health-related research and development based on the mission of
the NIH) mechanism. Further, grants (394) worth USD 147 million were
awarded to research projects related to endocannabinoid system.
At
present, therapies intended for the treatment of neurological disorders
represent the majority share of the overall endocannabinoid system targeted
therapeutics market
Most of the therapies targeting
neurological disorders are intended for the treatment of epilepsy. In addition
to neurological disorders, therapies intended for autoimmune disorders, cancer
and genetic disorders are likely to capture significant market opportunity in
the foreseen future.
To request a sample copy / brochure of this
report, please visit this - https://www.rootsanalysis.com/reports/316/request-sample.html
Key
Questions Answered
§
Who are the leading industry players in this market?
§
What are the key clinical conditions addressed by
endocannabinoid system targeted therapeutics?
§
What are the biological receptors targeted by cannabinoid-based
therapies?
§
What are the factors that are likely to influence the evolution
of this market?
§
What are the initiatives undertaken by start-ups and big pharma
players engaged in this domain?
§
What kind of partnership models are commonly adopted by
stakeholders in this industry?
§
How is the current and future market opportunity likely to be
distributed across key market segments?
The over USD 5 billion (by 2030)
financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the
following segments:
§
Target Disease Indication
§
Cancer
§
Genetic Disorders
§
Neurological Indications
§
Others
§
Route of Administration
§
Oral
§
Inhalation
§
Key Geographies
§
North America
§
Europe
§
Asia-Pacific and the Rest of the World
The
report features inputs from eminent industry stakeholders, according to whom,
endocannabinoid system targeted therapeutics are considered as a promising
alternative for the treatment of a diverse array of symptoms associated with a
myriad of human diseases. The report includes detailed transcripts of the
discussions held with industry experts.
The
research includes detailed profiles of key players (listed below); each profile
features an overview of the company, its
financial information (if available), drug portfolio, recent
developments and an informed future outlook.
§
GW Pharmaceuticals
§
Corbus Pharmaceuticals
§
Tilray
§
Tetra Bio-Pharma
§
Botanix Pharmaceuticals
§
Kalytera Therapeutics
§
Therapix Biosciences
§
Echo Pharmaceuticals
§
Avicanna
§
GB Sciences
For additional details, please
visit
https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
or email sales@rootsanalysis.com
You may also be interested in the
following titles:
1. Neoantigen Targeted
Therapies Market, 2019-2030
2.
Blood-Brain Barrier
(BBB) Market (2nd Edition), 2020-2030: Focus on
Non-Invasive Drug Delivery Technology Platforms and Therapeutics
3.
Bispecific Antibody
Therapeutics Market (4th
Edition), 2019-2030
4. Continuous
Manufacturing Market (Small Molecules and
Biologics), 2020 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
System Targeted Therapeutics Market By Roots Analysis
So far, more
than 100 different types of cannabinoids have been identified and there is a
growing body of evidence supporting the benefits of this class of compounds in
offering symptomatic relief for a wide variety of chronic health conditions
London
Roots Analysis has announced the
addition of “Endocannabinoid System Targeted Therapeutics Market,
2020-2030” report to its list of offerings.
Over
time, extensive R&D on the potential health benefits of cannabis, have
enabled medical researchers to identify a number of pharmacologically active
ingredients that offer clinical benefit, minus the addictive properties of the
crude substance. Currently, several stakeholders in the pharmaceutical industry
are actively engaged in the efforts to develop leads based on natural and
synthetic derivatives of cannabinoids.
To order this 250+ page report, which
features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Key Market
Insights
Over 175
drugs targeting the endocannabinoid system are currently under development
Most
cannabinoid-based drug candidates are being developed to target the CB1 and CB2
receptors. Nearly 45% of such drugs are presently being investigated in
clinical trials, while 50% are in the preclinical / discovery phase. Majority of these therapies (60%) are designed for
oral administration.
More than
60 companies claim to develop endocannabinoid system targeted therapeutics
Post
2010, there has been a significant rise in the number of companies working in this
domain; such companies represent 63% of the total number of players. Majority
of the firms engaged in this domain (74%) are based in North America, followed
by those headquartered in Asia-Pacific (16%), Europe (8%) and Latin America
(2%).
Partnership
activity has grown at an annualized rate of 35%, between 2017 and 2019
The
maximum number of partnerships were observed in 2019 within this segment of the
pharmaceutical industry. Majority of these agreements were reported to have
been inked for research purposes (20%). In addition, more than 35 merger /
acquisition deal were signed between 2016 and 2020; service / facility
expansion emerged as the most prominent key value drivers for such agreements.
Close to
600 grants were awarded for supporting research on endocannabinoid system
targeted therapeutics, since 2016
Almost
45% of the total amount awarded in the form of grants, was under the R01 (in
support of health-related research and development based on the mission of
the NIH) mechanism. Further, grants (394) worth USD 147 million were
awarded to research projects related to endocannabinoid system.
At
present, therapies intended for the treatment of neurological disorders
represent the majority share of the overall endocannabinoid system targeted
therapeutics market
Most of the therapies targeting
neurological disorders are intended for the treatment of epilepsy. In addition
to neurological disorders, therapies intended for autoimmune disorders, cancer
and genetic disorders are likely to capture significant market opportunity in
the foreseen future.
To request a sample copy / brochure of this
report, please visit this - https://www.rootsanalysis.com/reports/316/request-sample.html
Key
Questions Answered
§
Who are the leading industry players in this market?
§
What are the key clinical conditions addressed by
endocannabinoid system targeted therapeutics?
§
What are the biological receptors targeted by cannabinoid-based
therapies?
§
What are the factors that are likely to influence the evolution
of this market?
§
What are the initiatives undertaken by start-ups and big pharma
players engaged in this domain?
§
What kind of partnership models are commonly adopted by
stakeholders in this industry?
§
How is the current and future market opportunity likely to be
distributed across key market segments?
The over USD 5 billion (by 2030)
financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the
following segments:
§
Target Disease Indication
§
Cancer
§
Genetic Disorders
§
Neurological Indications
§
Others
§
Route of Administration
§
Oral
§
Inhalation
§
Key Geographies
§
North America
§
Europe
§
Asia-Pacific and the Rest of the World
The
report features inputs from eminent industry stakeholders, according to whom,
endocannabinoid system targeted therapeutics are considered as a promising
alternative for the treatment of a diverse array of symptoms associated with a
myriad of human diseases. The report includes detailed transcripts of the
discussions held with industry experts.
The
research includes detailed profiles of key players (listed below); each profile
features an overview of the company, its
financial information (if available), drug portfolio, recent
developments and an informed future outlook.
§
GW Pharmaceuticals
§
Corbus Pharmaceuticals
§
Tilray
§
Tetra Bio-Pharma
§
Botanix Pharmaceuticals
§
Kalytera Therapeutics
§
Therapix Biosciences
§
Echo Pharmaceuticals
§
Avicanna
§
GB Sciences
For additional details, please
visit
https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
or email sales@rootsanalysis.com
You may also be interested in the
following titles:
1. Neoantigen Targeted
Therapies Market, 2019-2030
2.
Blood-Brain Barrier
(BBB) Market (2nd Edition), 2020-2030: Focus on
Non-Invasive Drug Delivery Technology Platforms and Therapeutics
3.
Bispecific Antibody
Therapeutics Market (4th
Edition), 2019-2030
4. Continuous
Manufacturing Market (Small Molecules and
Biologics), 2020 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis